Objective: to assess the concentration of the sST2 biomarker and its relationship with the morphological and functional parameters of the LV myocardium in patients with coronary artery disease and chronic heart failure (CHF) l-lll functional class (FC), who had and did not have COVID-19. Material and methods. We examined 100 patients (66 males), median (Me) age 65 [63; 67] years, with stable coronary artery disease with CHF l-lll FC (New York Heart Association), divided into 2 groups depending on the COVID-19. Along with the conventional clinical examination, the concentration of serum sST2 was determined by enzyme immunoassay Results. It was found that in patients who underwent COVID-19 (group 1), the sST2 level was 38.4 [35.5; 44.8] ng/ml, in the comparison group (group 2) — 29.63 [27.9; 32.7] ng/ml (p<0.001). In group 1, the final diastolic volume and the final systolic volume of LV significantly exceeded those in group 2 (p=0.004 and p=0.02) and amounted to 118.2 [107.5; 166.5] and 44.1 [35.0; 58.1] ml, respectively, for the 1st and 107.5 [92.4; 129.5] and 37.9 [29.5; 47.4] ml for the 2nd group. The number of patients with grade 2 diastolic dysfunction (DD) in group 1 (18-33.9%) significantly exceeded that in the comparison group (7-14.9%). Changes in global longitudinal deformation of LV in COVID-19 group (-15.6 [-20.8; -13.8]%) were more pronounced than in the comparison group (-19.9 [-21.5; -16.3]%)(p=0.018). Conclusion. CHD patients with CHF l-lll FC and previous COVID-19, have significantly higher serum sST2, more pronounced LV DD and greater global longitudinal deformation.